Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 23Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Oxaliplatin 152Fluorouracil 137Gemcitabine 118Bevacizumab 116Leucovorin 106Specimen Handling 105Capecitabine 96pembrolizumab 90Magnetic Resonance Spectroscopy 83Nivolumab 79Cisplatin 79Irinotecan 71durvalumab 64Cetuximab 62Biopsy 61Paclitaxel 60130-nm albumin-bound paclitaxel 59Radiotherapy 46atezolizumab 45Albumin-Bound Paclitaxel 37Taxes 36Carboplatin 36Folfox protocol 35Drug Therapy 32Cyclophosphamide 30lenvatinib 29dehydroftorafur 29tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
enfortumab vedotin × Gastrointestinal × 90 days × Clear all
NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT06553885 2026-04-01

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡